Payment overview · 2025
General Payments
$1,188.70
82 reported records · 12 companies
Healthcare provider profile · identity verified
David Anthony Guerrero, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1265561849
Verified facts
What the public records show
CMS Open Payments records show David Anthony Guerrero, MD received $1,188.70 in general payments during 2025 across 82 reported records.
Lilly USA, LLC accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $247.59 | 20.8% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $213.18 | 17.9% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $167.92 | 14.1% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $162.59 | 13.7% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $92.11 | 7.8% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $67.71 | 5.7% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $58.57 | 4.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $57.53 | 4.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.28 | 3.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $31.94 | 2.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.99 | 2.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.29 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,188.70 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $230.30 | 19 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $167.92 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $126.40 | 8 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $107.97 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $95.40 | 9 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $58.57 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $57.53 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.99 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $45.28 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.21 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.21 | 8 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 23 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 947 | 343 |
| Amlodipine Besylate | Amlodipine Besylate | 477 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 428 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 341 | 118 |
| Metformin Hcl | Metformin Hcl | 317 | 128 |
| Lisinopril | Lisinopril | 295 | 100 |
| Montelukast Sodium | Montelukast Sodium | 256 | 103 |
| Alendronate Sodium | Alendronate Sodium | 252 | 95 |
| Losartan Potassium | Losartan Potassium | 251 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 84 |
| Pioglitazone Hcl | Pioglitazone Hcl | 193 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 71 |
| Gabapentin | Gabapentin | 178 | 79 |
| Famotidine | Famotidine | 174 | 75 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 164 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 64 |
| Carvedilol | Carvedilol | 138 | 54 |
| Furosemide | Furosemide | 136 | 53 |
| Omeprazole | Omeprazole | 128 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 47 |
| Finasteride | Finasteride | 115 | 37 |
| Meloxicam | Meloxicam | 109 | 55 |
| Potassium Chloride | Potassium Chloride | 108 | 41 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 106 | 38 |
| Januvia | Sitagliptin Phosphate | 106 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 38 |
| Allopurinol | Allopurinol | 104 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 36 |
| Tramadol Hcl | Tramadol Hcl | 100 | 40 |
| Ozempic | Semaglutide | 95 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 28 |
| Ibuprofen | Ibuprofen | 86 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 36 |
| Fenofibrate | Fenofibrate | 84 | 26 |
| Tradjenta | Linagliptin | 78 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | suppressed |
| Ezetimibe | Ezetimibe | 74 | 26 |
| Trazodone Hcl | Trazodone Hcl | 74 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 45 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 62 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 22 |
| Sertraline Hcl | Sertraline Hcl | 62 | 26 |
| Glimepiride | Glimepiride | 58 | 23 |
| Valsartan | Valsartan | 56 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 15 |
| Jardiance | Empagliflozin | 49 | 11 |
| Levofloxacin | Levofloxacin | 49 | 48 |
| Baclofen | Baclofen | 48 | 17 |
| Mirtazapine | Mirtazapine | 47 | 19 |
| Donepezil Hcl | Donepezil Hcl | 46 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 46 | 18 |
| Benazepril Hcl | Benazepril Hcl | 44 | 18 |
| Alprazolam | Alprazolam | 43 | 13 |
| Prednisone | Prednisone | 43 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | 18 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 15 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | 14 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Eliquis | Apixaban | 35 | 16 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 32 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 32 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 29 | 13 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 25 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | 11 |
| Farxiga | Dapagliflozin Propanediol | 26 | 11 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 25 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Clotrimazole | Clotrimazole | 24 | 18 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Cefdinir | Cefdinir | 20 | 20 |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Euthyrox | Levothyroxine Sodium | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 11 |
| Naproxen | Naproxen | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | 13 |
| Pregabalin | Pregabalin | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,188.70 · 82 records | Lilly USA, LLC | AIRSUPRA, AREXVY, Dexcom G6 Transmitter, FARXIGA, INSPIRE, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, Ozempic, REXULTI, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, Veozah, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error